Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

advanced breast cancer

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

Roche Basel Switzerland

Roche’s Gazyvaro cleared for follicular lymphoma in Europe

Second indication anticipated to increase peak sales by up to $1bn

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

AstraZeneca sells rights to seven anaesthetics in $770m deal

Ten-year agreement with Aspen continues the streamlining of its operations

Roche Basel Switzerland

Roche gets EU okay for Avastin/Tarceva combination

Lung cancer therapy ‘significantly’ extends progression-free survival

- PMLiVE

AstraZeneca to develop Lynparza companion diagnostic

Will collaborate with Foundation Medicine on test for its ovarian cancer drug

AstraZeneca AZ

AZ sells Zurampic rights to Gruenenthal for $230m

Continues to sell off unwanted assets in order to focus resources and meet $45bn sales target

Biomarin

BioMarin gives up on muscular dystrophy drug

Makes ‘difficult but necessary’ decision to abandon exon-skipping therapy Kyndrisa

- PMLiVE

GSK brings forward triple COPD therapy filing in US

Intends to file the three-drug respiratory therapy by the end of 2016

Daiichi Sankyo logo

Daiichi pulls study of patritumab in lung cancer

HER3 inhibitor candidate showed no evidence of efficacy in trial analysis

EU flag

Imbruvica wins wider European leukaemia licence

AbbVie and J&J’s first-in-class drug now approved to treat all CLL patients in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links